AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26413816 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-C. trachomatis IgG3 seropositivity
Number of subjects: 1250
Study 23419459 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA detrusor injections
Number of subjects: 10
Study 23419459 — intervention group
Group type: COMPARATOR
Intervention: Control (no OnabotulinumtoxinA injections)
Number of subjects: 10
Study 21233462 — intervention group
Group type: EXPERIMENTAL
Intervention: FAME therapy (family-mediated exercise therapy) for 8 weeks
Number of subjects: 40
Study 21233462 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy with no formal input from family members (Control)
Number of subjects: 40
Study 19436681 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 mg twice daily)
Number of subjects: 50
Study 19436681 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 17518883 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse short message service (SMS) intervention for six months
Number of subjects: 51
Study 17518883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS intervention)
Number of subjects: 51
Study 15361495 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet excluding all foods to which they had raised IgG antibodies
Number of subjects: 150
Study 15361495 — intervention group
Group type: COMPARATOR
Intervention: Sham diet excluding the same number of foods but not those to which they had antibodies
Number of subjects: 150
Study 11600749 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet free of gluten
Number of subjects: 66
Study 11600749 — intervention group
Group type: COMPARATOR
Intervention: Non-vegan diet
Number of subjects: 66
Study 11600749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study 10078794 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention package
Number of subjects: 236
Study 10078794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 236
Study 7979622 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day)
Number of subjects: 43
Study 7979622 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg four times a day)
Number of subjects: 43
Study 2692093 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 24
Study 2692093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral theophylline
Number of subjects: 24
Study 2692093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Respiratory Questionnaire (CRQ)
Number of subjects: 24
Study 2692093 — intervention group
Group type: EXPERIMENTAL
Intervention: Six Minute Walk Test
Number of subjects: 24
Study 2692093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating of dyspnea following the walk test
Number of subjects: 24
Study 2692093 — intervention group
Group type: EXPERIMENTAL
Intervention: CRQ dyspnea score
Number of subjects: 24
Study 1095114 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutrons
Number of subjects: 102
Study 1095114 — intervention group
Group type: COMPARATOR
Intervention: X or gamma rays (photons)
Number of subjects: 102
Study 31735700 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shockwave therapy (Li-ESWT)
Number of subjects: 0
Study 31735700 — intervention group
Group type: EXPERIMENTAL
Intervention: Li-ESWT
Number of subjects: 0
Study 30543483 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented ginseng (FG)
Number of subjects: 12
Study 30543483 — intervention group
Group type: COMPARATOR
Intervention: Nonfermented ginseng (NFG)
Number of subjects: 12
Study 28608496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenously pantoprazole 40 mg once daily
Number of subjects: 3350
Study 26244837 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline (Group 1)
Number of subjects: 51
Study 26244837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin solution (Group 2)
Number of subjects: 51
Study 26244837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin solution (Group 3)
Number of subjects: 51
Study 23280086 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL‐2 regimen (cytarabine 3 g/m(2) daily for 5 days with mitoxantrone 80 mg/m(2))
Number of subjects: 164
Study 23280086 — intervention group
Group type: COMPARATOR
Intervention: L‐20 regimen (standard 4‐drug induction)
Number of subjects: 164
Study 23280086 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL‐2 regimen
Number of subjects: 164
Study 23280086 — intervention group
Group type: COMPARATOR
Intervention: L‐20 regimen
Number of subjects: 164
Study 21975270 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 DNA (4 mg) at day 0 followed by H5N1 monovalent inactivated vaccine (MIV; 90 μg) at 24 weeks
Number of subjects: 81
Study 21975270 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 DNA (4 mg) at day 0 followed by H5N1 MIV at week 4
Number of subjects: 81
Study 21975270 — intervention group
Group type: COMPARATOR
Intervention: Two-dose regimen of H5N1 MIV with a 4 or 24 week interval
Number of subjects: 81
Study 21975270 — intervention group
Group type: EXPERIMENTAL
Intervention: H5 DNA (4 mg) at day 0 followed by H5N1 MIV at week 24
Number of subjects: 81
Study 18155496 — intervention group
Group type: EXPERIMENTAL
Intervention: Morinda citrifolia juice (MCJ)
Number of subjects: 60
Study 18155496 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (NaOCl)
Number of subjects: 60
Study 18155496 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHX)
Number of subjects: 60
Study 18155496 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control)
Number of subjects: 60
Study 16442203 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic uterine nerve ablation (LUNA)
Number of subjects: 80
Study 16442203 — intervention group
Group type: COMPARATOR
Intervention: Vaginal uterosacral ligament resection (VUSR)
Number of subjects: 80
Study 14632330 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 22
Study 10630453 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 35
Study 10630453 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 35
Study 10630453 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 35
Study 9093646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.10 mg.kg‐1)
Number of subjects: 30
Study 9093646 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.50 mg.kg‐1)
Number of subjects: 30
Study 9093646 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.16 mg.kg‐1) after Pancuronium
Number of subjects: 30
Study 9093646 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium (0.03 mg.kg‐1)
Number of subjects: 30
Study 1868024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential combination chemotherapy: cyclophosphamide, doxorubicin, 5-fluorouracil, followed by cisplatin and hexamethylmelamine
Number of subjects: 301
Study 1868024 — intervention group
Group type: COMPARATOR
Intervention: 3-drug combination alternating with the 2-drug combination every other month
Number of subjects: 301
Study 1868024 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic index calculated for each patient
Number of subjects: 301
Study 7133974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen 200 mg
Number of subjects: 210
Study 7133974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen 400 mg
Number of subjects: 210
Study 7133974 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocin 100 mg
Number of subjects: 210
Study 7133974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 30339929 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distancing group
Number of subjects: 65
Study 30339929 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-immersed group
Number of subjects: 65
Study 30339929 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 27680540 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS ≤2.4 (BeSt-study)
Number of subjects: 1109
Study 27680540 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS <1.6 (IMPROVED-study)
Number of subjects: 1109
Study 27680540 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence in BeSt-study
Number of subjects: 1109
Study 27680540 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence in IMPROVED-study
Number of subjects: 1109
Study 27680540 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence in both studies
Number of subjects: 1109
Study 27680540 — intervention group
Group type: EXPERIMENTAL
Intervention: DAS <1.6 steered protocol
Number of subjects: 1109
Study 25369587 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 120
Study 25369587 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 120
Study 23265757 — intervention group
Group type: COMPARATOR
Intervention: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of saline four hourly (single dose group)
Number of subjects: 60
Study 23265757 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of amoxycillin 1.0 g preoperatively followed by two postoperative doses of amoxycillin 0.5 g four hourly (short course group)
Number of subjects: 60
Study 20608879 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal patch with two drug-containing layers (20% and 80% concentrations) and a barrier layer (14% thickness)
Number of subjects: 0
Study 19185242 — intervention group
Group type: EXPERIMENTAL
Intervention: epi‐Shugarcaine solution (epinephrine 0.025% and lidocaine 0.75% in fortified balanced salt solution [BSS Plus])
Number of subjects: 42
Study 19185242 — intervention group
Group type: COMPARATOR
Intervention: Lundberg and Behndig's intracameral dilation solution (cyclopentolate 0.1%, phenylephrine 1.5%, and lidocaine 1%)
Number of subjects: 42
Study 17332444 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice (MP) sessions, 30 minutes, 2 days/week for 6 weeks, directly after therapy
Number of subjects: 32
Study 17332444 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention (relaxation), same therapist interaction as MP group
Number of subjects: 32
Study 15026102 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an individually tailored and administered educational intervention promoting safe-driving strategies
Number of subjects: 403
Study 15026102 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comprehensive eye examination)
Number of subjects: 403
Study 11490107 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge and continued rehabilitation at home
Number of subjects: 83
Study 11490107 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation
Number of subjects: 83
Study 10649160 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly fetal surveillance
Number of subjects: 167
Study 10649160 — intervention group
Group type: COMPARATOR
Intervention: Fortnightly fetal surveillance
Number of subjects: 167
Study 9150703 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (LRT) 0.04 g i.m. once every 2 weeks for 3 months
Number of subjects: 5
Study 9150703 — intervention group
Group type: COMPARATOR
Intervention: Water injection i.m. once every 2 weeks for 3 months (Control)
Number of subjects: 5
Study 8103874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alteplase (100 mg over 3 h)
Number of subjects: 5711
Study 8103874 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 5711
Study 3789690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alc A (60% isopropyl alcohol with emollients)
Number of subjects: 50
Study 3789690 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG (4% chlorhexidine gluconate and 4% IPA)
Number of subjects: 50
Study 3789690 — intervention group
Group type: EXPERIMENTAL
Intervention: IPA (70% isopropyl alcohol)
Number of subjects: 50
Study 3789690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alc B (70% IPA and 0.5% chlorhexidine gluconate with emollients)
Number of subjects: 50
Study 3789690 — intervention group
Group type: COMPARATOR
Intervention: Control (nonantiseptic liquid soap)
Number of subjects: 50
Study 3789690 — intervention group
Group type: EXPERIMENTAL
Intervention: All antiseptics
Number of subjects: 50
Study 3789690 — intervention group
Group type: EXPERIMENTAL
Intervention: All agents
Number of subjects: 50
Study 3789690 — intervention group
Group type: EXPERIMENTAL
Intervention: Subject assessment of effects of hand washing
Number of subjects: 50
Study 30166409 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified CPAP (10 cm H2O)
Number of subjects: 15
Study 30166409 — intervention group
Group type: COMPARATOR
Intervention: Non-humidified CPAP (10 cm H2O)
Number of subjects: 15
Study 27131462 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin levels
Number of subjects: 572
Study 27131462 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic control
Number of subjects: 572
Study 24499812 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy
Number of subjects: 446
Study 24499812 — intervention group
Group type: COMPARATOR
Intervention: Salpingectomy
Number of subjects: 446
Study 24499812 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingotomy and Salpingectomy
Number of subjects: 446
Study 22275250 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Rep1 genotype
Number of subjects: 0
Study 22275250 — intervention group
Group type: EXPERIMENTAL
Intervention: Long Rep1 genotype
Number of subjects: 0
Study 22275250 — intervention group
Group type: COMPARATOR
Intervention: Head injury
Number of subjects: 0
Study 22275250 — intervention group
Group type: EXPERIMENTAL
Intervention: Head injury in those with long Rep1
Number of subjects: 0
Study 22275250 — intervention group
Group type: EXPERIMENTAL
Intervention: Head injury and long Rep1
Number of subjects: 0
Study 20049907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin
Number of subjects: 255
Study 18686764 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive Xeno III with microhybrid resin composite Esthet-X
Number of subjects: 60
Study 18686764 — intervention group
Group type: COMPARATOR
Intervention: Etch-and-rinse adhesive OptiBond Solo Plus with Point 4 microhybrid resin composite
Number of subjects: 60
Study 18686764 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 16194792 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 0
Study 12911119 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP extrafine aerosol (maximum 800 microg/day)
Number of subjects: 716
Study 10478227 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG gating
Number of subjects: 35
Study 8712129 — intervention group
Group type: EXPERIMENTAL
Intervention: First-phase polarity of biphasic waveform
Number of subjects: 0
Study 8712129 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-phase polarity of biphasic waveform
Number of subjects: 0
Study 1919305 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg administered 10 minutes after 5 mg epidural morphine
Number of subjects: 40
Study 1919305 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 40
Study 30265882 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) - 3 doses of 2g at 4, 10, and 16 hours postoperatively
Number of subjects: 0
Study 30265882 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (TXA) - 3 doses of 1g at 6, 12, and 18 hours postoperatively
Number of subjects: 0
Study 30265882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (oral and intravenous TXA)
Number of subjects: 0
Study 27597724 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 every five days for 3 months
Number of subjects: 94
Study 27597724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 24691394 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week online face-training program targeting holistic face processing
Number of subjects: 24
Study 24691394 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week online face-training program targeting holistic face processing (for 'better' trainees)
Number of subjects: 24
Study 24691394 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported diary improvements
Number of subjects: 24
Study 24691394 — intervention group
Group type: COMPARATOR
Intervention: Waiting period (control group)
Number of subjects: 24
Study 22694488 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 37
Study 22694488 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 37
Study 20379947 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified mesh materials
Number of subjects: 0
Study 20379947 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal meshes, parastomal meshes, meshes in areas with bacterial contamination, meshes in the hiatus region
Number of subjects: 0
Study 20379947 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control assessments of explanted implant failures
Number of subjects: 0
Study 18342952 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with antidepressants
Number of subjects: 0
Study 18342952 — intervention group
Group type: COMPARATOR
Intervention: Usual care without antidepressants
Number of subjects: 0
Study 16377699 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (100 mg loading dose followed by 50 mg maintenance dose of BAL4815)
Number of subjects: 8
Study 16377699 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL8557 (200 mg loading dose followed by 100 mg maintenance dose of BAL4815)
Number of subjects: 8
Study 16377699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12729001 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture (5.6 g twice daily)
Number of subjects: 22
Study 12729001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 10910479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.2 mg/kg
Number of subjects: 75
Study 10910479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.4 mg/kg
Number of subjects: 75
Study 10910479 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 75
Study 8902961 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program (Group 1, n = 74)
Number of subjects: 205
Study 8902961 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (Group II, n = 64)
Number of subjects: 205
Study 8902961 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group III, n = 67)
Number of subjects: 205
Study 1528643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis-diphtheria tetanus toxoids vaccine (APDT)
Number of subjects: 397
Study 1528643 — intervention group
Group type: COMPARATOR
Intervention: Whole cell DTP vaccine
Number of subjects: 397
Study 4067799 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (responses different than test 1)
Number of subjects: 50
Study 4067799 — intervention group
Group type: COMPARATOR
Intervention: Control group (repeated test 1 answers)
Number of subjects: 50
Study 4067799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 4067799 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 30932300 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 101
Study 30932300 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 101
Study 29228087 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab + FOLFIRI
Number of subjects: 1072
Study 29228087 — intervention group
Group type: COMPARATOR
Intervention: placebo + FOLFIRI
Number of subjects: 1072
Study 26923773 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen (2.2 mg/kg per os every 12 hours for 7 days)
Number of subjects: 12
Study 26923773 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel capsule (per os every 12 hours for 7 days)
Number of subjects: 12
Study 25270900 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM33 (33°C)
Number of subjects: 171
Study 25270900 — intervention group
Group type: COMPARATOR
Intervention: TTM36 (36°C)
Number of subjects: 171
Study 22382633 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a (180 μg) plus ribavirin
Number of subjects: 201
Study 22382633 — intervention group
Group type: COMPARATOR
Intervention: PegIFNα‐2b (60-150 μg) plus ribavirin
Number of subjects: 201
Study 22382633 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a (180 μg) plus ribavirin in IL28B TT genotype patients
Number of subjects: 201
Study 22382633 — intervention group
Group type: COMPARATOR
Intervention: PegIFNα‐2b (60-150 μg) plus ribavirin in IL28B TT genotype patients
Number of subjects: 201
Study 22382633 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNα‐2a (180 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years
Number of subjects: 201
Study 22382633 — intervention group
Group type: COMPARATOR
Intervention: PegIFNα‐2b (60-150 μg) plus ribavirin in patients weighing <60 kg, women, and patients aged >60 years
Number of subjects: 201
Study 20635030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitapex paste
Number of subjects: 90
Study 20635030 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste
Number of subjects: 90
Study 20635030 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper points of povidone iodine
Number of subjects: 90
Study 17651479 — intervention group
Group type: COMPARATOR
Intervention: Conventional quadruple therapy (QT) - omeprazole 20 mg bid, bismuth citrate 120 mg qid, tetracycline 500 mg qid, metronidazole 500 mg tid for 7 days
Number of subjects: 99
Study 17651479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin-based triple therapy (OAR) - omeprazole 20 mg bid, amoxicillin 1 gr bid, rifabutin 150 mg bid for 7 days
Number of subjects: 99
Study 17651479 — intervention group
Group type: COMPARATOR
Intervention: Conventional quadruple therapy (QT)
Number of subjects: 99
Study 17651479 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin-based triple therapy (OAR)
Number of subjects: 99